Payment overview · 2025
General Payments
$559.93
18 reported records · 9 companies
Healthcare provider profile · identity verified
Robert R. Ramirez, M.D,
Allopathic & Osteopathic Physicians|Internal Medicine · NEW BRAUNFELS, TX · NPI 1285606996
Verified facts
What the public records show
CMS Open Payments records show Robert R. Ramirez, M.D, received $559.93 in general payments during 2025 across 18 reported records.
Genentech USA, Inc. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Shingrix, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $117.86 | 21.1% | 1 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $112.25 | 20.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.98 | 17.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $87.68 | 15.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.77 | 11.4% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.12 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.24 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.16 | 3.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.87 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $559.93 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Xolair Normalized: xolair |
Biological | Genentech USA, Inc., Genentech, Inc. | $230.11 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $96.98 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.05 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $63.77 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 42 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
42 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
99 | 69 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 692 | 227 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 537 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 472 | 146 |
| Losartan Potassium | Losartan Potassium | 445 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 391 | 134 |
| Lisinopril | Lisinopril | 318 | 100 |
| Metformin Hcl | Metformin Hcl | 256 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 92 |
| Gabapentin | Gabapentin | 241 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 67 |
| Alendronate Sodium | Alendronate Sodium | 176 | 60 |
| Omeprazole | Omeprazole | 162 | 58 |
| Carvedilol | Carvedilol | 159 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 59 |
| Sertraline Hcl | Sertraline Hcl | 156 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 57 |
| Trazodone Hcl | Trazodone Hcl | 149 | 58 |
| Furosemide | Furosemide | 142 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 56 |
| Metformin Hcl Er | Metformin Hcl | 123 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 38 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 106 | 86 |
| Montelukast Sodium | Montelukast Sodium | 106 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 50 |
| Celecoxib | Celecoxib | 99 | 42 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 99 | 69 |
| Donepezil Hcl | Donepezil Hcl | 97 | 30 |
| Eliquis | Apixaban | 95 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 88 | 27 |
| Famotidine | Famotidine | 80 | 37 |
| Ezetimibe | Ezetimibe | 74 | 26 |
| Ozempic | Semaglutide | 74 | 21 |
| Glimepiride | Glimepiride | 72 | 21 |
| Azelastine Hcl | Azelastine Hcl | 69 | 36 |
| Allopurinol | Allopurinol | 67 | 22 |
| Memantine Hcl | Memantine Hcl | 62 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 17 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 61 | 61 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 18 |
| Prednisone | Prednisone | 52 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 18 |
| Simvastatin | Simvastatin | 51 | 20 |
| Buspirone Hcl | Buspirone Hcl | 50 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 22 |
| Bupropion Xl | Bupropion Hcl | 48 | 17 |
| Potassium Chloride | Potassium Chloride | 48 | 20 |
| Mirtazapine | Mirtazapine | 46 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 40 |
| Topiramate | Topiramate | 45 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 42 | 42 |
| Jardiance | Empagliflozin | 42 | 15 |
| Glipizide Er | Glipizide | 40 | 13 |
| Myrbetriq | Mirabegron | 40 | 15 |
| Januvia | Sitagliptin Phosphate | 39 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 15 |
| Novolog Flexpen | Insulin Aspart | 38 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 24 |
| Spironolactone | Spironolactone | 37 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 33 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 36 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | 14 |
| Linzess | Linaclotide | 35 | 11 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 15 |
| Naproxen | Naproxen | 34 | 18 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 28 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Glipizide | Glipizide | 30 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | 14 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Tradjenta | Linagliptin | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Clotrimazole | Clotrimazole | 21 | 15 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 12 |
| Cephalexin | Cephalexin | 18 | 17 |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Fluconazole | Fluconazole | 16 | 11 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $559.93 · 18 records | Genentech USA, Inc. | AREXVY, Cologuard Collection Kit, FARXIGA, INSPIRE, KISUNLA, Kerendia, Repatha, SHINGRIX, TRELEGY ELLIPTA, Xolair | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error